TRIM33 and cancer: Anti-TIF1γ antibodies: Anti-TIF-1γ antibodies, previously named as anti-p155 antibodies, have been identified as myositis-specific autoantibodies and represent a significant and major risk factor for cancer-associated dermatomyositis (83, 113–115).